600436.SH
片仔癀
SSE · Healthcare · Drug Manufacturers - General · CN
CNY 123.76
−0.27%Year over year
Reported trailing growth
- Revenue
- -20.1%
- EBITDA
- —
- EBIT
- -37.6%
- EPS
- -36.7%
- Free cash flow
- -89.3%
- Operating cash flow
- -73.4%
Forward estimates
Based on analyst estimates
- Revenue
- -11.6%
- EBITDA
- +12.8%
- EPS
- +24.6%
Three-year CAGR
- Revenue
- +1.2%
- EBITDA
- -4.6%
- EBIT
- -5.1%
- Net income
- -4.4%
- EPS
- -4.4%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026